Keywords: Pfizer, Lipitor, Generic atorvastatin, Ranbaxy, Hylan Phelps & McNamara, US exclusivity

Outlook for generic equivalent of Pfizer’s Lipitor; how will US exclusivity resolve? asks law firm HPM

Article | 14 October 2010

Print This

2011 is shaping up to be an interesting year in the Hatch-Waxman world, and all eyes seem to be focusing on ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in